Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches

This activity is intended for hematologic oncology physicians, nurses, pharmacists, and advanced practice clinicians who provide care for individuals with hematologic malignancies, especially follicular lymphoma.

After completing this activity, the participant should be better able to:

• Apply prognostic tools to the evaluation and management of patients with FL, including patients with hallmarks of aggressive disease
• Compare and contrast mechanisms of action, efficacy data, and toxicity profiles for new and emerging therapies, including for third-line and later treatment settings in FL
• Select therapies for patients with RR FL in consideration of prior therapy, disease factors, patient factors, and treatment goals

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

ECMEC^® Credit

The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMA-EACCME^®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)^TM into European CME credit (ECMEC^®) should contact the UEMS (www.uems.eu).

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA0007322-9999-23-067-L01-P
Type of Activity:  Application

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

• Standard approaches to care in FL and implications of prognostic markers

• The latest clinical evidence and guideline recommendations for treatment decision-making in FL and common TRAEs (treatment-related adverse events)

• Patient-related factors that play an important role in access to novel therapies for FL and improved outcomes

• Q&A with Faculty

Krish Patel, MD
Director, Lymphoma Program
Director, Hematologic Malignancies and Cellular Therapy
Center for Blood Disorders and Cellular Therapy
Swedish Cancer Institute
Seattle, WA

Adrienne Phillips, MD, MPH
Director of Cell Therapy and Bone Marrow Transplantation, Northern Regions, RWJ Barnabas Health and Rutgers Cancer Institute of NJ
New York, NY

Tycel Phillips, MD
Associate Professor of Medicine
City of Hope
Duarte, CA